Novel Neuraminidase Inhibitor Shows Promise against H5N1 Avian Influenza Virus

By LabMedica International staff writers
Posted on 11 Mar 2010

Drug developers have shown that the novel antiviral neuraminidase inhibitor R-125489 administered as its prodrug CS-8958 works effectively against the highly pathogenic influenza A virus H5N1 (the avian influenza virus), including oseltamivir (Tamiflu)-resistant strains.

An international team of virologists and infectious disease experts from as far a field as the University of Wisconsin (Madison, USA) and the University of Kobe (Japan) reported in the February 26, 2010, online edition of the journal PLoS Pathogens that a single dose of CS-8958 given to mice two hours after infection with H5N1 influenza viruses produced a higher survival rate than did continuous five-day administration of oseltamivir. More...

Virus titers in lungs and brain were substantially lower in infected mice treated with a single dose of CS-8958 than in those treated with the five-day course of oseltamivir. Furthermore, a single dose of CS-8958 given seven days prior to virus exposure also protected mice against H5N1 virus lethal infection.

At the molecular level, the investigators found that R-125489 bound to the viral neuraminidase more tightly than did any other neuraminidase inhibitor tested. Summing up, the authors wrote that, "Our results indicate that CS-8958 is highly effective for the treatment and prophylaxis of infection with H5N1 influenza viruses, including oseltamivir-resistant mutants.”

Related Links:
University of Wisconsin
University of Kobe

Visit expo >

New

Gold Member

Blood Gas Analyzer

Stat Profile pHOx

POC Helicobacter Pylori Test Kit
Hepy Urease Test

New

Capillary Blood Collection Tube

IMPROMINI M3

New

Urine Chemistry Control

Dropper Urine Chemistry Control

Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.

Free digital version edition of LabMedica International sent by email on regular basis
Free print version of LabMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of LabMedica International in digital format
Free LabMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!